Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

We recently published a list of Renaissance Technologies Portfolio: 10 Best Stocks To Buy. In this article, we are going to ...

Novo Nordisk AS (NVO) reports a 25% sales increase, upgrades its full-year outlook, and addresses challenges in the insulin ...

Shares in WeightWatchers surged by nearly 38% in extended hours trading on Wednesday, pointing to an extension in sharp gians ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Questor is The Telegraph’s stockpicking column, helping you decode the markets and offering insights on where to invest for ...

A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

American adults prefer dietary change as a weight loss method, over injectable weight loss drugs such as Ozempic, a survey says.

Shares of WeightWatchers parent company WW International ($WW) have rocketed 40% higher on news that the company plans to ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Medicare’s costs could balloon by the low to middle tens of billions of dollars over 10 years due to the cost of covering GLP-1 drugs for obesity.